Group 1 - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 14,351 million in 2025, with USD 8,266 million from the U.S. and USD 6,085 million from the rest of the world [1][5] - Genmab receives royalties on the worldwide net sales of DARZALEX, which includes both intravenous and subcutaneous products, under an exclusive license agreement with Johnson & Johnson [1][5] - The company has a strong late-stage clinical pipeline and is focused on delivering transformative antibody-based medicines to patients [2] Group 2 - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a global presence across North America, Europe, and Asia Pacific [3] - Genmab has been dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines for over 25 years [2]

Core Insights - Johnson & Johnson announced positive topline results from the Phase 3 MajesTEC-9 study, demonstrating that TECVAYLI monotherapy reduced the risk of disease progression or death by 71% and the risk of death by 40% in a patient population largely refractory to existing therapies [1][5][6] Group 1: Study Results - The MajesTEC-9 study confirmed superior progression-free survival (PFS) and overall survival (OS) with TECVAYLI compared to standard care as early as second line therapy [1][2] - The study involved patients who were predominantly refractory to anti-CD38 monoclonal antibodies (85%) and lenalidomide (79%), with over 90% being refractory to their last line of therapy [4][5] - TECVAYLI's safety profile was manageable, with no new safety concerns identified, and the Independent Data Monitoring Committee recommended unblinding the study based on the strength of the data [5][6] Group 2: Treatment Context - Multiple myeloma is characterized by high relapse rates and a significant unmet need for additional therapies, particularly for patients refractory to commonly used treatments [2][3] - The results from MajesTEC-9 build on previous findings from the MajesTEC-3 study, which showed significant benefits of TECVAYLI in combination with DARZALEX FASPRO for patients who were naïve or sensitive to anti-CD38 therapy [2][3] Group 3: Future Implications - The results from the MajesTEC-9 study position TECVAYLI as a potential new standard of care for multiple myeloma treatment, particularly for patients experiencing their first relapse [3][6] - Johnson & Johnson continues to innovate in the multiple myeloma space, aiming to redefine treatment options and improve outcomes for patients at all stages of the disease [6][8]

Core Insights - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 3,672 million in Q3 2025, with USD 2,088 million from the U.S. and USD 1,584 million from the rest of the world [1][5] Company Overview - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with a vision to transform cancer treatment by 2030 [2] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3]

Company Performance - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 3,539 million in Q2 2025, with USD 2,017 million from the U.S. and USD 1,521 million from the rest of the world [1][5] - The company receives royalties on the worldwide net sales of DARZALEX, which includes both intravenous and subcutaneous products, under an exclusive license agreement with Johnson & Johnson [1][5] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve patient lives, with a vision to transform cancer treatment by 2030 [2] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3]

Company Announcement - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 3,237 million in Q1 2025, with USD 1,829 million from the U.S. and USD 1,409 million from the rest of the world [1][5] - Genmab receives royalties on the worldwide net sales of DARZALEX, which includes both intravenous and subcutaneous products, under an exclusive license agreement with Johnson & Johnson [1][5] About Genmab - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve patient lives, with a vision to transform cancer treatment by 2030 [2] - The company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators [2] Company Background - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a presence in North America, Europe, and Asia Pacific [3]